Research
Hormonal
GLP-1 receptor agonists (GLP-1 RAs) have shown promising potential in promoting weight loss and preventing diseases associated with obesity.
GLP-1 RAs may be considered as a pharmacologic option for obesity treatment.
StrongSupportsmedium confidence
Researchers are particularly interested in 1 type of drug, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), because of its promising potential in addressing the limitations of non-pharmacologic treatments.
Why this rating
The review discusses the effectiveness of GLP-1 RAs based on existing research.
Source
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Fatima Ali Raza et al. · Medicine · 2024
DOI 10.1097/md.0000000000040364
reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →